ChemoCentryx CCXI shares are trading lower on Thursday after the company announced topline data from its Phase II AURORA clinical trial of Avacopan in the treatment of Hidradenitis Suppurativa.
ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer.
ChemoCentryx shares were trading down 6.90% at $48.64 on Thursday. The stock has a 52-week high of $65.43 and a 52-week low of $7.88.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
